A new article published in the European Journal of Preventive Cardiology demonstrated that sodium-glucose co-transporter-2 (SGLT2) inhibitors, such as canagliflozin, significantly reduce the incidence of mortality, major adverse cardiac events, non-fatal myocardial infarction and heart failure in patients with type-2 diabetes mellitus. The purpose of this study was to ascertain the risks and benefits of SGLT2 inhibitors on cardiovascular outcomes. A review of evidence from all available clinical trials was conducted to assess the cardiovascular effects of this drug. Here, electronic databases, MEDLINE, Scopus, CENTRAL and clinicaltrials.gov, were searched from their inception through July 2017 for published and unpublished placebo controlled trials on SGLT2 inhibitors. The results from 35 eligible studies revealed that SGLT2 inhibitors, markedly reduce all-cause mortality, major adverse cardiac events, non-fatal myocardial infarction and heart failure or hospitalizations due to heart failure in patients with type-2 diabetes mellitus.